ACC House Call: Usability of Novel VTE Risk Score with Deepak Bhatt, MD


A discussion on a study from ACC.20 examining use of a novel genetic risk score to predict VTE in patients with cardiometabolic disease.

New data from the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) suggest a novel 10-SNP genetic risk score shows promise for predicting the risk of venous thromboembolism (VTE) in patients with cardiometabolic disease.

Created by a team of investigators from the TIMI Study Group, Harvard Medical School, and the Board Institute of MIT and Harvard, the novel risk score was designed and assessed in more than 30,000 patients with cardiometabolic disease from the FOURIER, PEGASUS-TIMI 54, and SAVOR-TIMI 53 trials.

Dividing patients into textiles based on 3 categories of risk, investigators used a Cox proportional hazards model to assess hazard ratios for VTE across the risk categories while adjusting for age, sex, and ancestry. In addition to the risk of VTE, the analysis also assesses the risk of myocardial infarction, coronary heart disease, and ischemic stroke. Of the 31,669 patients included, 193 had a VTE event over a median follow-up period of 2.4 years.

The analysis revealed a significant increased gradient of risk for VTE across the 3 categories of risk (P-trend <.0001). When adjusting for the aforementioned confounders, results indicated patients in the intermediate (HR 1.65, 1.09-2.49, P=.017) and high (HR 2.80, 1.92-4.10, P <.0001) genetic categories were at greater risk of VTE compared to those in the lowest genetic risk category. Additionally, investigators observed each standard deviation increase in genetic risk score correlated to a 38% increase in risk for VTE.

For more on this study and the potential of risk scores in a clinical setting, we caught up with Deepak Bhatt, MD, study investigator and executive director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital, in a recent ACC House Call.

This study, “Performance of a Novel Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients with Cardiometabolic Disease,” was presented at ACC.20/WCC.

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
© 2024 MJH Life Sciences

All rights reserved.